ORIC PHARMACEUTICALS, INC. financials

ORIC CIK 0001796280

Source: EDGAR filings · Built 2026-06-02T03:45:19Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -111.68M -113.85M -86.54M -77.22M -60.48M -45.94M
EBITDA -141.78M -141.79M -109.75M -90.80M -77.97M -73.22M
Working Capital 268.05M 237.40M 192.14M 195.07M 225.37M 287.69M
Net Debt -38.23M -50.05M -13.17M -54.74M -203.06M -78.45M
Return on Equity (ROE) -33.68% -52.59% -44.94% -40.08% -28.84% -25.43%
Return on Assets (ROA) -31.66% -46.64% -39.96% -36.06% -26.36% -24.65%
Current Ratio 14.13× 10.55× 10.39× 13.68× 15.88× 32.96×
Debt-to-Equity 0.02× 0.04× 0.05× 0.05× 0.08× 0.00×
Cash Conversion Ratio 0.86× 0.88× 0.85× 0.84× 0.76× 0.61×
Accruals Ratio -0.05× -0.06× -0.06× -0.06× -0.06× -0.10×
CapEx Coverage -155.86× -94.83× -100.93× -36.16× -63.41× -67.87×
Free Cash Flow Per Share $-1.27 $-1.63 $-1.68 $-1.95 $-1.59 $-2.09

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/B 2.10× 2.36× 2.25× 1.19× 2.12× 4.28×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Operating Expenses 143.00M 142.90M 110.78M 91.77M 78.87M 74.19M
Operating Income (Loss) -143.00M -142.90M -110.78M -91.77M -78.87M -74.19M
Income Tax Expense (Benefit) 0 0 0 0 0 0
Net Income (Loss) Attributable to Parent -129.47M -127.85M -100.70M -89.12M -78.72M -73.70M
Earnings Per Share, Basic $-1.47 $-1.83 $-1.96 $-2.25 $-2.07
Weighted Average Number of Shares Outstanding, Basic 87.79M 69.73M 51.45M 39.66M 37.95M
Earnings Per Share, Diluted $-1.47 $-1.83 $-1.96 $-2.25 $-2.07
Weighted Average Number of Shares Outstanding, Diluted 87.79M 69.73M 51.45M 39.66M 37.95M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 45.67M 59.41M 23.38M 66.84M 226.01M 78.45M
Assets, Current 288.47M 262.25M 212.60M 210.46M 240.52M 296.70M
Assets 408.89M 274.14M 252.01M 247.18M 298.64M 299.00M
Long-term Debt 10.50M
Liabilities, Current 20.42M 24.85M 20.46M 15.39M 15.15M 9.00M
Liabilities 24.53M 31.02M 27.92M 24.83M 25.67M 9.22M
Stockholders' Equity Attributable to Parent 384.36M 243.12M 224.09M 222.35M 272.98M 289.78M
Common Stock, Shares, Outstanding 98.53M 71.02M 54.87M 45.09M 39.43M 36.67M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -110.97M -112.66M -85.69M -75.14M -59.54M -45.27M
Payments to Acquire Property, Plant, and Equipment 712.00K 1.19M 849.00K 2.08M 939.00K 667.00K
Net Cash Provided by (Used in) Investing Activities -148.03M 22.14M -43.40M -109.25M 158.44M -215.96M
Net Cash Provided by (Used in) Financing Activities 245.26M 126.55M 85.66M 25.23M 49.13M 250.51M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (ORIC CIK 0001796280), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

CNXC

CONCENTRIX CORPORATION

LVWR

LiveWire Group, Inc.

TGTX

TG THERAPEUTICS, INC.